BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

Provided By PR Newswire

Last update: Apr 17, 2024

Bob Dagher, MD, Promoted to Chief Medical Officer

Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors

NEW YORK, April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Dr. Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors. These strategic management changes are being made as the Company prepares to embark on a registrational Phase 3b trial for NurOwn^®, its investigational cell therapy treatment for amyotrophic lateral sclerosis (ALS).